Dr. Mike Gosselin Selected to Lead Aprecia’s Product Development Team


Gosselin’s scientific and solution-focused leadership will guide the development of new 3DP products from early innovation to commercial productiontion.

CINCINNATI, April 13, 2022 /PRNewswire/ — Aprecia Pharmaceuticals today announced that it has chosen Mike Gosselin, Ph.D., as Vice President of Pharmaceutical Development. Gosselin will oversee product development, from early innovation to commercial production, at Aprecia’s 3DP Center of Excellence in Blue Ash, Ohio.

“Aprecia will continue to grow at a rapid pace by licensing our new 3DP formulation platforms to enable development and enhance product value in partnership,” said Chris Gilmore, CEO of Aprecia. “We continue to add accomplished scientists to fulfill our mission to deliver unique products through global partnerships. I am pleased to welcome Mike to this important leadership role in ensuring that we exceed expectations in our product development programs.

“Aprecia’s 3D printing technology platforms provide a new level of creative freedom and manufacturing agility to help product formulators overcome the constraints of conventional pharmaceutical manufacturing technologies,” said Gosselin. “I am honored to join the 3DP industry leaders at Aprecia, and look forward to collaborating with our customers to design new dosage forms, accelerate time to market and reduce product development costs. »

Gosselin is a seasoned executive with 20 years of experience managing people and projects in pharmaceutical development and manufacturing operations. He has extensive experience in dosage formulation and process development, scale-up, validation, and manufacturing of solid products in oral, liquid, and liquid-filled capsules.

About Aprecia Pharmaceuticals, LLC
Founded in 2003, Aprecia received the first and only three-dimensional printing (3DP) prescription drug approval approved by the FDA. This groundbreaking achievement opened the door to the FDA for the entire industry. Aprecia’s ZipDose® technology creates fast-disintegrating oral dosage forms that are easy to take and administer, including engineered and coated particles for low and high dose products (over 1000mg). Aprecia directly owns an area of ​​patents for new 3DP equipment and 3DP pharmaceutical applications. It licenses its proprietary technology platform as a specialty CDMO to pharmaceutical partners to expand product lines, improve patient reach and experience, and help meet FDA requirements for pediatric delivery forms. For more information, visit www.aprecia.com.

SOURCEAprecia Pharmaceuticals


Comments are closed.